Literature DB >> 24687502

Bumped kinase inhibitor 1294 treats established Toxoplasma gondii infection.

J Stone Doggett1, Kayode K Ojo2, Erkang Fan3, Dustin J Maly4, Wesley C Van Voorhis5.   

Abstract

Toxoplasma gondii is a unicellular parasite that causes severe brain and eye disease. Current drugs for T. gondii are limited by toxicity. Bumped kinase inhibitors (BKIs) selectively inhibit calcium-dependent protein kinases of the apicomplexan pathogens T. gondii, cryptosporidia, and plasmodia. A lead anti-Toxoplasma BKI, 1294, has been developed to be metabolically stable and orally bioavailable. Herein, we demonstrate the oral efficacy of 1294 against toxoplasmosis in vivo.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24687502      PMCID： PMC4068437          DOI： 10.1128/AAC.01823-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  12 in total

1.  Toxoplasma gondii calcium-dependent protein kinase 1 is a target for selective kinase inhibitors.

Authors:  Kayode K Ojo; Eric T Larson; Katelyn R Keyloun; Lisa J Castaneda; Amy E Derocher; Krishna K Inampudi; Jessica E Kim; Tracy L Arakaki; Ryan C Murphy; Li Zhang; Alberto J Napuli; Dustin J Maly; Christophe L M J Verlinde; Frederick S Buckner; Marilyn Parsons; Wim G J Hol; Ethan A Merritt; Wesley C Van Voorhis
Journal:  Nat Struct Mol Biol       Date:  2010-05-02       Impact factor: 15.369

2.  Acute toxoplasmoses in immunocompetent patients hospitalized in an intensive care unit in French Guiana.

Authors:  M Demar; D Hommel; F Djossou; C Peneau; R Boukhari; D Louvel; A-M Bourbigot; V Nasser; D Ajzenberg; M-L Darde; B Carme
Journal:  Clin Microbiol Infect       Date:  2011-09-29       Impact factor: 8.067

3.  Multiple determinants for selective inhibition of apicomplexan calcium-dependent protein kinase CDPK1.

Authors:  Eric T Larson; Kayode K Ojo; Ryan C Murphy; Steven M Johnson; Zhongsheng Zhang; Jessica E Kim; David J Leibly; Anna M W Fox; Molly C Reid; Edward J Dale; B Gayani K Perera; Jae Kim; Stephen N Hewitt; Wim G J Hol; Christophe L M J Verlinde; Erkang Fan; Wesley C Van Voorhis; Dustin J Maly; Ethan A Merritt
Journal:  J Med Chem       Date:  2012-03-13       Impact factor: 7.446

4.  Discovery of Potent and Selective Inhibitors of Calcium-Dependent Protein Kinase 1 (CDPK1) from C. parvum and T. gondii.

Authors:  Ryan C Murphy; Kayode K Ojo; Eric T Larson; Alejandro Castellanos-Gonzalez; B Gayani K Perera; Katelyn R Keyloun; Jessica E Kim; Janhavi G Bhandari; Natascha R Muller; Christophe L M J Verlinde; A Clinton White; Ethan A Merritt; Wesley C Van Voorhis; Dustin J Maly
Journal:  ACS Med Chem Lett       Date:  2010-10-14       Impact factor: 4.345

5.  Development of Toxoplasma gondii calcium-dependent protein kinase 1 (TgCDPK1) inhibitors with potent anti-toxoplasma activity.

Authors:  Steven M Johnson; Ryan C Murphy; Jennifer A Geiger; Amy E DeRocher; Zhongsheng Zhang; Kayode K Ojo; Eric T Larson; B Gayani K Perera; Edward J Dale; Panqing He; Molly C Reid; Anna M W Fox; Natascha R Mueller; Ethan A Merritt; Erkang Fan; Marilyn Parsons; Wesley C Van Voorhis; Dustin J Maly
Journal:  J Med Chem       Date:  2012-02-27       Impact factor: 7.446

6.  Calcium-dependent protein kinase 1 is an essential regulator of exocytosis in Toxoplasma.

Authors:  Sebastian Lourido; Joel Shuman; Chao Zhang; Kevan M Shokat; Raymond Hui; L David Sibley
Journal:  Nature       Date:  2010-05-20       Impact factor: 49.962

7.  Optimizing small molecule inhibitors of calcium-dependent protein kinase 1 to prevent infection by Toxoplasma gondii.

Authors:  Sebastian Lourido; Chao Zhang; Michael S Lopez; Keliang Tang; Jennifer Barks; Qiuling Wang; Scott A Wildman; Kevan M Shokat; L David Sibley
Journal:  J Med Chem       Date:  2013-03-26       Impact factor: 7.446

8.  A novel calcium-dependent protein kinase inhibitor as a lead compound for treating cryptosporidiosis.

Authors:  Alejandro Castellanos-Gonzalez; A Clinton White; Kayode K Ojo; Rama S R Vidadala; Zhongsheng Zhang; Molly C Reid; Anna M W Fox; Katelyn R Keyloun; Kasey Rivas; Ayesha Irani; Sara M Dann; Erkang Fan; Dustin J Maly; Wesley C Van Voorhis
Journal:  J Infect Dis       Date:  2013-07-21       Impact factor: 5.226

9.  Ocular sequelae of congenital toxoplasmosis in Brazil compared with Europe.

Authors:  Ruth E Gilbert; Katherine Freeman; Eleonor G Lago; Lilian M G Bahia-Oliveira; Hooi Kuan Tan; Martine Wallon; Wilma Buffolano; Miles R Stanford; Eskild Petersen
Journal:  PLoS Negl Trop Dis       Date:  2008-08-13

10.  Identification of mutations in TgMAPK1 of Toxoplasma gondii conferring resistance to 1NM-PP1.

Authors:  Tatsuki Sugi; Kyousuke Kobayashi; Hitoshi Takemae; Haiyan Gong; Akiko Ishiwa; Fumi Murakoshi; Frances C Recuenco; Tatsuya Iwanaga; Taisuke Horimoto; Hiroomi Akashi; Kentaro Kato
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2013-05-18       Impact factor: 4.077
View more
  37 in total

Review 1.  Designing selective inhibitors for calcium-dependent protein kinases in apicomplexans.

Authors:  Raymond Hui; Majida El Bakkouri; L David Sibley
Journal:  Trends Pharmacol Sci       Date:  2015-05-20       Impact factor: 14.819

2.  Novel Bumped Kinase Inhibitors Are Safe and Effective Therapeutics in the Calf Clinical Model for Cryptosporidiosis.

Authors:  Deborah A Schaefer; Dana P Betzer; Kylie D Smith; Zachary G Millman; Hannah C Michalski; Sarah E Menchaca; Jennifer A Zambriski; Kayode K Ojo; Matthew A Hulverson; Samuel L M Arnold; Kasey L Rivas; Rama S R Vidadala; Wenlin Huang; Lynn K Barrett; Dustin J Maly; Erkang Fan; Wesley C Van Voorhis; Michael W Riggs
Journal:  J Infect Dis       Date:  2016-10-17       Impact factor: 5.226

Review 3.  Extended-spectrum antiprotozoal bumped kinase inhibitors: A review.

Authors:  Wesley C Van Voorhis; J Stone Doggett; Marilyn Parsons; Matthew A Hulverson; Ryan Choi; Samuel L M Arnold; Michael W Riggs; Andrew Hemphill; Daniel K Howe; Robert H Mealey; Audrey O T Lau; Ethan A Merritt; Dustin J Maly; Erkang Fan; Kayode K Ojo
Journal:  Exp Parasitol       Date:  2017-01-05       Impact factor: 2.011

4.  Development of an Orally Available and Central Nervous System (CNS) Penetrant Toxoplasma gondii Calcium-Dependent Protein Kinase 1 (TgCDPK1) Inhibitor with Minimal Human Ether-a-go-go-Related Gene (hERG) Activity for the Treatment of Toxoplasmosis.

Authors:  Rama Subba Rao Vidadala; Kasey L Rivas; Kayode K Ojo; Matthew A Hulverson; Jennifer A Zambriski; Igor Bruzual; Tracey L Schultz; Wenlin Huang; Zhongsheng Zhang; Suzanne Scheele; Amy E DeRocher; Ryan Choi; Lynn K Barrett; Latha Kallur Siddaramaiah; Wim G J Hol; Erkang Fan; Ethan A Merritt; Marilyn Parsons; Gail Freiberg; Kennan Marsh; Dale J Kempf; Vern B Carruthers; Nina Isoherranen; J Stone Doggett; Wesley C Van Voorhis; Dustin J Maly
Journal:  J Med Chem       Date:  2016-07-01       Impact factor: 7.446

5.  Optimizing Pyrazolopyrimidine Inhibitors of Calcium Dependent Protein Kinase 1 for Treatment of Acute and Chronic Toxoplasmosis.

Authors:  James W Janetka; Allen T Hopper; Ziping Yang; Jennifer Barks; Mary Savari Dhason; Qiuling Wang; L David Sibley
Journal:  J Med Chem       Date:  2020-06-01       Impact factor: 7.446

6.  Toxoplasma Calcium-Dependent Protein Kinase 1 Inhibitors: Probing Activity and Resistance Using Cellular Thermal Shift Assays.

Authors:  Suzanne Scheele; Jennifer A Geiger; Amy E DeRocher; Ryan Choi; Tess R Smith; Matthew A Hulverson; Rama Subba Rao Vidadala; Lynn K Barrett; Dustin J Maly; Ethan A Merritt; Kayode K Ojo; Wesley C Van Voorhis; Marilyn Parsons
Journal:  Antimicrob Agents Chemother       Date:  2018-05-25       Impact factor: 5.191

7.  Pharmacokinetics and In Vivo Efficacy of Pyrazolopyrimidine, Pyrrolopyrimidine, and 5-Aminopyrazole-4-Carboxamide Bumped Kinase Inhibitors against Toxoplasmosis.

Authors:  Matthew A Hulverson; Igor Bruzual; Erin V McConnell; Wenlin Huang; Rama S R Vidadala; Ryan Choi; Samuel L M Arnold; Grant R Whitman; Molly C McCloskey; Lynn K Barrett; Kasey L Rivas; Suzanne Scheele; Amy E DeRocher; Marilyn Parsons; Kayode K Ojo; Dustin J Maly; Erkang Fan; Wesley C Van Voorhis; J Stone Doggett
Journal:  J Infect Dis       Date:  2019-04-16       Impact factor: 5.226

8.  Development of a murine vertical transmission model for Toxoplasma gondii oocyst infection and studies on the efficacy of bumped kinase inhibitor (BKI)-1294 and the naphthoquinone buparvaquone against congenital toxoplasmosis.

Authors:  Joachim Müller; Adriana Aguado-Martínez; Luis-Miguel Ortega-Mora; Javier Moreno-Gonzalo; Ignacio Ferre; Matthew A Hulverson; Ryan Choi; Molly C McCloskey; Lynn K Barrett; Dustin J Maly; Kayode K Ojo; Wes Van Voorhis; Andrew Hemphill
Journal:  J Antimicrob Chemother       Date:  2017-08-01       Impact factor: 5.790

9.  Two Novel Calcium-Dependent Protein Kinase 1 Inhibitors Interfere with Vertical Transmission in Mice Infected with Neospora caninum Tachyzoites.

Authors:  Joachim Müller; Adriana Aguado-Martínez; Vreni Balmer; Dustin J Maly; Erkang Fan; Luis-Miguel Ortega-Mora; Kayode K Ojo; Wesley C Van Voorhis; Andrew Hemphill
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

Review 10.  Review of Experimental Compounds Demonstrating Anti-Toxoplasma Activity.

Authors:  Madalyn M McFarland; Sydney J Zach; Xiaofang Wang; Lakshmi-Prasad Potluri; Andrew J Neville; Jonathan L Vennerstrom; Paul H Davis
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.